A Pilot Study of a Heparin Dosing Algorithm for Hemodialysis

Heparin Dose Reduction During Hemodialysis With the Gambro Revaclear and Revaclear MAX Hemodialyzers: Pilot Study I and II

During hemodialysis treatments, patients receive heparin to prevent clotting. The purpose of this pilot study is to determine if the amount of heparin administered during a patient's hemodialysis can be individualized using an equation for heparin dose adjustment.

Inclusion Criteria:

• Adults 18 years of age or older
• Stable hemodialysis prescription prior to study enrollment
• Dialyzing through a native fistula or Gore-Tex graft
• Blood access must be able to provide a blood flow rate of 400 ml/min

Exclusion Criteria:

• Non-compliance with dialysis
• Hematocrit less than 28%
• Active Infection
• Diagnosis of Heparin-Induced Thrombocytopenia (HIT)